Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale

Ann Oncol. 2018 May 1;29(5):1330-1331. doi: 10.1093/annonc/mdy107.

Authors

T Masuishi¹, H Taniguchi², K Sugiyama¹, K Kato¹, S Mitani¹, K Honda¹, Y Narita¹, S Kadowaki¹, T Ura¹, M Ando¹, K Muro¹

Affiliations

¹ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
² Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Electronic address: [email protected].

PMID: 29635451
DOI: 10.1093/annonc/mdy107

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / metabolism
Aged
CA-19-9 Antigen / blood
Colorectal Neoplasms / diagnostic imaging
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / pathology
Disease Progression
Fatal Outcome
Female
Furans / pharmacology
Furans / therapeutic use*
Humans
Ketones / pharmacology
Ketones / therapeutic use*
Male
Middle Aged
Mitosis / drug effects
Mutation
Proto-Oncogene Proteins B-raf / genetics
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden / drug effects

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
CA-19-9 Antigen
Furans
Ketones
BRAF protein, human
Proto-Oncogene Proteins B-raf
eribulin